Advertisement

Liver Diseases pp 273-284 | Cite as

Nonalcoholic Fatty Liver Disease: A Wide Spectrum Disease

  • Natalia RossoEmail author
  • Stefano BellentaniEmail author
Chapter

Abstract

Nonalcoholic Liver Disease (NAFLD) is considered a wide spectrum progressive disease and has emerged as a major cause of chronic liver disease worldwide. It has a global prevalence of 24%, an increasing incidence in both adults and children, in parallel with the pandemic burden of obesity, Type 2 Diabetes Mellitus (T2DM) and Metabolic Syndrome (MS). The pathogenic drivers are still unknown and are not likely to be identical among all patients. The natural history of NAFLD is not linear: it progresses to Nonalcoholic Steatohepatitis (NASH) in 10–30% of the cases, and about 10–15% of NASH patients progress to cirrhosis. The major cause of mortality of NAFLD patients is cardiovascular disease (CVD), being liver-related mortality only the third cause. New valid markers to distinguish patients who progress to either cirrhosis or CVD and new treatments are still to be developed. In spite of the great efforts devoted to achieving these goals, real options for new non-invasive markers for the diagnosis of NASH-cirrhosis and new therapeutic agents are still limited. This chapter will discuss the most updated data about the epidemiology, risk factors, pathogenesis, available experimental models, new diagnostic tools and new treatment options for NAFLD and NASH.

Keywords

Steatosis NonAlcoholic Fatty Liver Disease (NAFLD) NonAlcoholic SteatoHepatitis (NASH) Lipotoxicity Oxidative stress Fibrosis 

References

  1. 1.
    Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–8.PubMedGoogle Scholar
  2. 2.
    Bellentani S, Tiribelli C. Is it time to change NAFLD and NASH nomenclature? Lancet Gastroenterol Hepatol. 2017;2:547–8.CrossRefGoogle Scholar
  3. 3.
    Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.CrossRefGoogle Scholar
  4. 4.
    Younossi ZM, Henry L, Bush H, Mishra A. Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis. 2018;22:1–10.CrossRefGoogle Scholar
  5. 5.
    Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988–1994 to 2007–2010. J Pediatr. 2013;162:496–500.e1.CrossRefGoogle Scholar
  6. 6.
    Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63:827–38.CrossRefGoogle Scholar
  7. 7.
    Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–5.CrossRefGoogle Scholar
  8. 8.
    Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1209–17.CrossRefGoogle Scholar
  9. 9.
    Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology. 2016;150:1219–1230.e6.CrossRefGoogle Scholar
  10. 10.
    Anstee QM, Seth D, Day CP. Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease. Gastroenterology. 2016;150:1728–1744.e7.CrossRefGoogle Scholar
  11. 11.
    Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med. 2018;378:1096–106.CrossRefGoogle Scholar
  12. 12.
    Zarrinpar A, Gupta S, Maurya MR, Subramaniam S, Loomba R. Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut. 2016;65:1546–54.CrossRefGoogle Scholar
  13. 13.
    Leung JC-F, Loong TC-W, Wei JL, Wong GL-H, Chan AW-H, Choi PC-L, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017;65:54–64.CrossRefGoogle Scholar
  14. 14.
    Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126:12–22.CrossRefGoogle Scholar
  15. 15.
    Yki-Järvinen H. Nutritional modulation of non-alcoholic fatty liver disease and insulin resistance. Nutrients. 2015;7:9127–38.CrossRefGoogle Scholar
  16. 16.
    Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120–7.CrossRefGoogle Scholar
  17. 17.
    Alegre F, Pelegrin P, Feldstein AE. Inflammasomes in liver fibrosis. Semin Liver Dis. 2017;37:119–27.CrossRefGoogle Scholar
  18. 18.
    Mazza G, Al-Akkad W, Rombouts K. Engineering in vitro models of hepatofibrogenesis. Adv Drug Deliv Rev. 2017;121:147–57.CrossRefGoogle Scholar
  19. 19.
    van Grunsven LA. 3D in vitro models of liver fibrosis. Adv Drug Deliv Rev. 2017;121:133–46.CrossRefGoogle Scholar
  20. 20.
    Van Herck MA, Vonghia L, Francque SM. Animal models of nonalcoholic fatty liver disease—a starter’s guide. Nutrients. 2017;9  https://doi.org/10.3390/nu9101072.CrossRefGoogle Scholar
  21. 21.
    Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397.e10.CrossRefGoogle Scholar
  22. 22.
    Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.CrossRefGoogle Scholar

Related Published Articles

  1. Araújo AR, Rosso N, Bedogni G, Tiribelli C, Bellentani S. Global epidemiology of NAFLD/NASH: what we need in the future. Liver Int. 2018;38(Suppl 1):47–51.CrossRefGoogle Scholar
  2. Barbero-Becerra VJ, Giraudi PJ, Chávez-Tapia NC, Uribe M, Tiribelli C, Rosso N. The interplay between hepatic stellate cells and hepatocytes in an in vitro model of NASH. Toxicol In Vitro. 2015;29(7):1753–8.  https://doi.org/10.1016/j.tiv.2015.07.010. PMID: 26187275.CrossRefPubMedGoogle Scholar
  3. Chavez-Tapia NC, Rosso N, Tiribelli C. In vitro models for the study of non-alcoholic fatty liver disease. Curr Med Chem. 2011;18(7):1079–84.CrossRefGoogle Scholar
  4. Giraudi PJ, Barbero Becerra VJ, Marin V, Chavez-Tapia NC, Tiribelli C, Rosso N. The importance of the interaction between hepatocyte and hepatic stellate cells in fibrogenesis induced by fatty accumulation. Exp Mol Pathol. 2014;98(1):85–92.  https://doi.org/10.1016/j.yexmp.2014.12.006.CrossRefPubMedGoogle Scholar
  5. Marin V, Rosso N, Dal Ben M, Raseni A, Boschelle M, Degrassi C, et al. An animal model for the juvenile non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. PLoS One. 2016;11(7):e0158817.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Fondazione Italiana FegatoBasovizzaItaly
  2. 2.Clinica Santa Chiara SALocarnoSwitzerland

Personalised recommendations